Oklahoma bioscience firm working to make a major impact on cancer battle

DormaTarg is developing therapeutics to deal with recurrence in metastasis-prone cancers.

Oklahoma is building a reputation nationwide as a place where discoveries in bioscience lead to groundbreaking solutions that can have a real impact on people’s lives.

One exciting example is DormaTarg, an Oklahoma-based firm that is developing therapeutics to deal with one of the toughest challenges in fighting cancer — inhibiting the recurrence in metastasis-prone cancers.

“We have a drug that we believe targets dormant cells before they reactivate and can prevent cancer from metastasizing — going from a primary to a secondary site,” said Michael Ihnat, DormaTarg’s director of drug development.